AssetMark’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
Other funds holding RCUS
SL
AssetMark's RCUS Position: Q3 2026 in Review
AssetMark opened a new position in Arcus Biosciences (RCUS) in Q3 2026: 13 shares worth $336. The stake represents ﹤0.01% of the portfolio and ranks #3521 among its holdings. This is a return to the name: AssetMark previously reported a position in RCUS as recently as Q1 2025.
AssetMark first reported a position in RCUS in Q1 2025 and has held it in 2 quarters since. The position peaked at $338 in Q1 2025. 171 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.
- AssetMark held 13 shares of Arcus Biosciences worth $336 as of Q3 2026.
- Arcus Biosciences was a new AssetMark position in Q3 2026.
- Arcus Biosciences made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3521 holding.
- AssetMark first reported a position in Arcus Biosciences in Q1 2025 and has held it in 2 quarters since.
- AssetMark's Arcus Biosciences position peaked at $338 in Q1 2025.
- 171 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.